Genetic associations of autopsy-confirmed vascular dementia subtypes

Dementia and Geriatric Cognitive Disorders

Volumn 31, Issue 4, 2011, Pages 247-253

  Jones, Emma L ^a   Kalaria, Rajesh N ^b   Sharp, Sally I ^c   O'Brien, John T ^b   Francis, Paul T ^a   Ballard, Clive G ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Cerebrovascular disease; Genetics; Stroke

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; CHOLINE ACETYLTRANSFERASE; INTERCELLULAR ADHESION MOLECULE 1; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ARTICLE; AUTOPSY; CEREBROVASCULAR DISEASE; DEMOGRAPHY; DISEASE ASSOCIATION; ENZYME ACTIVITY; GENETIC ASSOCIATION; HEART INFARCTION; HUMAN; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; RISK FACTOR; STROKE;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; CHOLINE O-ACETYLTRANSFERASE; DEMENTIA, VASCULAR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; RISK FACTORS; STROKE;

EID: 79953720023     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000327171     Document Type: Article

References (47)

1. O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST: Vascular cognitive impairment. Lancet Neurol 2003; 2: 89-98. (Pubitemid 37443329)
2. Heyman A, Fillenbaum GG, Welsh-Bohmer KA, Gearing M, Mirra SS, Mohs RC, Peterson BL, Pieper CF: Cerebral infarcts in patients with autopsy-proven Alzheimer's disease. CERAD Part XVIII. Neurology 1998; 51: 159-162; erratum 1809. (Pubitemid 28345377)
3. Savva GM, Stephan BC: Epidemiological studies of the effect of stroke on incident dementia: a systematic review. Stroke 2010; 41:e41-e46.
4. Kokmen E, Whisnant JP, O'Fallon WM, Chu CP, Beard CM: Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960-1984). Neurology 1996; 46: 154-159. (Pubitemid 26156122)
5. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC: Subcortical ischaemic vascular dementia. Lancet Neurol 2002; 1: 426-436. (Pubitemid 37159153)
6. Lewis H, Beher D, Cookson N, Oakley A, Piggott M, Morris CM, Jaros E, Perry R, Ince P, Kenny RA, Ballard CG, Shearman MS, Kalaria RN: Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid- ( 42) peptide in vascular dementia. Neuropathol Appl Neurobiol 2006; 32: 103-118.
7. Firbank MJ, Burton EJ, Barber R, Stephens S, Kenny RA, Ballard C, Kalaria RN, O'Brien JT: Medial temporal atrophy rather than white matter hyperintensities predict cognitive decline in stroke survivors. Neurobiol Aging 2007; 28: 1664-1669. (Pubitemid 47384946)
8. Corder EH, Saunders AM, Strittmater WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late-onset families. Science 1993; 261: 921-923. (Pubitemid 23275809)
9. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD: Apolipoprotein E: high-avidity binding to- -amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 1977-1981.
10. Kim JS: Cytokines and adhesion molecules in stroke and related diseases. J Neurol Sci 1996; 137: 69-78. (Pubitemid 26172036)
11. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, Rozen R: A candidate genetic risk factor for vascular disease: a common mutation methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
12. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ: Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 1994; 272: 1666-1671. (Pubitemid 24359137)
13. Ballard CG, Morris CM, Rao H, O'Brien JT, Barber R, Stephens S, Rowan E, Gibson A, Kalaria RN, Kenny RA: APOE- 4 and cognitive decline in older stroke patients with early cognitive impairment. Neurology 2004; 63: 1399-1402.
14. Wagle J, Farner L, Flekkøy K, Wyller TB, Sandvik L, Eiklid KL, Fure B, Stensrød B, Engedal K: Association between ApoE- 4 and cognitive impairment after stroke. Dement Geriatr Cogn Disord 2009; 27: 525-533.
15. Wagle J, Farner L, Flekkøy K, Wyller TB, Sandvik L, Eiklid KL, Fure B, Stensrød B, Engedal K: Cognitive impairment and the role of the ApoE- 4 allele after stroke - a 13-month follow-up study. Int J Geriatr Psychiatry 2010; 25: 833-842.
16. Mortimer JA, Snowdon DA, Markesbery WR: The effect of APOE- 4 on dementia is mediated by Alzheimer neuropathology. Alzheimer Dis Assoc Disord 2009; 23: 152-157.
17. Drzezga A, Grimmer T, Henriksen G, Mühlau M, Perneczky R, Miederer I, Praus C, Sorg C, Wohlschläger A, Riemenschneider M, Wester HJ, Foerstl H, Schwaiger M, Kurz A: Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 2009; 72: 1487-1494.
18. Alafuzoff I, Helisalmi S, Mannermaa A, Soininen H: Severity of cardiovascular disease, apolipoprotein E genotype, and brain pathology in aging and dementia. Ann N Y Acad Sci 2000; 903: 244-251. (Pubitemid 30251564)
19. Soininen H, Kosunen O, Helisalmi S, Mannermaa A, Paljärvi L, Talasniemi S, Ryynä nen M, Riekkinen P: A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein- 4 allele. Neurosci Lett 1995; 187: 79-82.
20. Allen SJ, MacGowan SH, Tyler S, Wilcock GK, Robertson AG, Holden PH, Smith SK, Dawbarn D: Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein- 4 genotype. Neurosci Lett 1997; 239: 33-36. (Pubitemid 28055843)
21. Thomas AJ, Perry R, Kalaria RN, Oakley A, McMeekin W, O'Brien JT: Neuropathological evidence for ischemia in the white matter of the dorsolateral prefrontal cortex in latelife depression. Int J Geriatr Psychiatry 2003; 18: 7-13. (Pubitemid 36131222)
22. Pola R, Flex A, Gaetani E, Papaleo P, De Martini D, Gerardino L, Serricchio M, Pola P, Bernabei R: Association between intercellular adhesion molecule-1 E/K gene polymorphism and probable vascular dementia in humans. Neurosci Lett 2002; 326: 171-174. (Pubitemid 34722452)
23. Pola R, Flex A, Gaetani E, Santoliquido A, Serricchio M, Pola P, Bernabei R: Intercellular adhesion molecule-1 K469E gene polymorphism and Alzheimer's disease. Neurobiol Aging 2003; 24: 385-387. (Pubitemid 36005418)
24. Verbeek MM, Otte-Höller I, Westphal JR, Wesseling P, Ruiter DJ, de Waal RM: Accumulation of intercellular adhesion molecule- 1 in senile plaques in brain tissue of patients with Alzheimer's disease. Am J Pathol 1994; 144: 104-116. (Pubitemid 24158364)
25. Lehmann M, Gottfries CG, Regland B: Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord 1999; 10: 12-20. (Pubitemid 28567038)
26. Riggs KM, Spiro A 3rd, Tucker K, Rush D: Relations of vitamin B -12 , vitamin B -6 , folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr 1996; 63: 306-314. (Pubitemid 26074688)
27. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM: Folate, vitamin B 12 , and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998; 55: 1449-1455. (Pubitemid 28525506)
28. Joosten E, Lesaffre E, Riezler R, Ghekiere V, Dereymaeker L, Pelemans W, Dejaeger E: Is metabolic evidence for vitamin B -12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? Gerontol A Biol Sci Med Sci 1997; 52:M76-M79. (Pubitemid 27123966)
29. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP: Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 2002; 33: 2351-2356.
30. Yoo JH, Choi GD, Kang SS: Pathogenicity of thermolabile methylenetetrahydrofolate reductase for vascular dementia. Arterioscler Thromb Vasc Biol 2000; 20; 1921-1925.
31. Zhang CE, Wei W, Liu YH, Peng JH, Tian Q, Liu GP, Zhang Y, Wang JZ: Hyperhomocysteinemia increases- -amyloid by enhancing expression of- -secretase and phosphorylation of amyloid precursor protein in rat brain. Am J Pathol 2009; 174: 1481-1491.
32. Selley ML, Close DR, Stern SE: The effect of increased concentrations of homocysteine on the concentration of ( E )-4-hydroxy-2- nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol Aging 2002; 23: 383-388. (Pubitemid 34312021)
33. Pedersen WA, Cashman NR, Mattson MP: The lipid peroxidation product 4-hydroxynonenal impairs glutamate and glucose transport and choline acetyltransferase activity in NSC-19 motor neuron cells. Exp Neurol 1999; 155: 1-10. (Pubitemid 29072599)
34. Sharp SI, Francis PT, Elliott MS, Kalaria RN, Bajic N, Hortobagyi T, Ballard CG: Choline acetyltransferase activity in vascular dementia and stroke. Dement Geriatr Cogn Disord 2009; 28: 233-238.
35. Clarke EE, Shearman MS: Quantitation of amyloid- peptides in biological milieu using a novel homogeneous time-resolved fluorescence (HTFR) assay. J Neurosci Methods 2000; 102: 61-68.
36. Fonnum F: A rapid radiochemical method for the determination of choline acetyltransferase. J Neurochem 1975; 242: 407-409.
37. Minger SL, Esiri MM, McDonald B, Keene J, Carter J, Hope T, Francis PT: Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 2000; 55: 1460-1467.
38. Del Ser T, Barba R, Morin MM, Domingo J, Cemillan C, Pondal M, Vivancos J: Evolution of cognitive impairment after stroke and risk factors for delayed progression. Stroke 2005: 36: 2670-2675.
39. Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C: A- -peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol 2001; 281:H2417-H2424.
40. Guglielmotto M, Tamagno E, Danni O: Oxidative stress and hypoxia contribute to Alzheimer's disease pathogenesis: two sides of the same coin. ScientificWorldJournal 2009; 9: 781-791.
41. Van Dijk EJ, Prins ND, Vermeer SE, Hofman A, van Duijn CM, Koudstaal PJ, Breteler MM: Plasma amyloid- , apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 2004; 55; 570-575.
42. Ye S, Huang Y, Müllendorff K, Dong L, Giedt G, Meng EC, Cohen FE, Kuntz ID, Weisgraber KH, Mahley RW: Apolipoprotein (apo) E4 enhances amyloid- peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc Natl Acad Sci USA 2005; 102: 18700-18705.
43. Darvesh S, Walsh R, Martin E: Homocysteine thiolactone and human cholinesterases. Cell Mol Neurobiol 2007; 27: 33-48. (Pubitemid 46169893)
44. Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV, GAL-INT-6 Study Group: An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther 2003; 25: 1765-1782.
45. Erratum in: Clin Ther 2003; 25: 2336.
46. Erkinjuntti T, Gauthier S, Bullock R, Kurz A, Hammond G, Schwalen S, Zhu Y, Brashear R: Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6). J Psychopharmacol 2008; 2: 761-768.
47. Ballard C, Sauter M, Scheltens P He Y, Barkhof F, van Straaten EC, van der Flier WM, Hsu C, Wu S, Lane R: Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin 2008; 24: 2561-2574.